Navigation Links
Cumberland Pharmaceuticals Appoints Lee Product Director
Date:1/13/2009

NASHVILLE, Tenn., Jan. 13 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. is pleased to announce the appointment of Barry Lee as Product Director. In this role, Mr. Lee will draw upon his 24 years of pharmaceutical sales and marketing experience to lead the prospective launch and commercialization of new products for the company.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090113/CLTU094 )

"We are extremely pleased to welcome Mr. Lee to Cumberland's management team," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "As we work to continue to grow the company, we believe Barry's extensive experience and solid track record of success will be extremely valuable in helping Cumberland deliver promising new products to patients who can benefit."

Mr. Lee joins Cumberland from Bayer Healthcare Pharmaceuticals where he held a variety of sales and marketing positions during his 24-year tenure. In addition to leading sales training and development efforts, he oversaw the launch of the company's Yasmin(R) product, which was one of the most successful industry launches of its time, reaching $92 million in net sales its first year on the market. Under his leadership, the product grew to $320 million in net sales over a four-year period. Mr. Lee is a graduate of Texas A & M University.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company that develops and markets branded, prescription products for targeted physician segments, including hospital acute care and gastroenterology. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Cumberland Pharmaceuticals web site at www.cumberlandpharma.com.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
2. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
3. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
4. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
5. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
6. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
7. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
8. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
9. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
10. AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development
11. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 that ... test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific for ... NAT screening for blood donors under an Investigational New Drug (IND) study protocol. ...
(Date:4/25/2017)... ... ... As part of the Stago EdVantage Virtual University Virtual Event, ... order to illuminate this clinical problem for people unfamiliar with the topic. , DIC ... high degree of morbidity and mortality. DIC is a confusing disorder from both diagnostic ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Metrology Partners.     , Covalent’s Analytical Services unit provides high-quality data to ... measured within 24 hours of receipt. There are no price premiums, and customers ...
(Date:4/21/2017)... ... ... Having worked on the design of the innovative Triton™ lab bench ... lab design architects from around the country at the Lab Design Conference 2017 in ... Greg Casey will be at the show, where they will highlight the unique elements ...
Breaking Biology Technology:
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):